About Medicine Magazine

Health | Biotechnology | Pharmaceutical

Health Headlines

November 26, 2024 08:45 AM Eastern Time

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

Opens in new window

Download

Full Size JPEG, 2034x615, 434.5 KB
Small JPEG, 480x145, 44.5 KB
Preview JPEG, 144x44, 7.9 KB
Thumbnail JPEG, 120x36, 6.3 KB

Smart Multimedia Gallery

http://www.businesswire.com/multimedia/houstonmedicine/20241126785516/en/5753131/Lantern-Pharma-Starlight-Therapeutics-Present-LP-184-STAR-001-Phase-1b-Trial-Design-and-Preclinical-Data-in-Glioblastoma-at-Society-for-Neuro-Oncology-SNO-2024-Highlighting-Novel-Synthetic-Lethality

Share

All News | News with Multimedia > Press Release: Lantern Pharma & Starlight Therapeutics Present...

Get Business Wire News on Your Website

Terms of Use | © 2024 Business Wire

Medical News | Articles | TV & Video | Authors | About Houston Medicine | Subscribe | Advertising | Masthead | Contact Us

Copyright 2004. World Publishing LLC. All rights reserved.